Introduction
O-GlcNAcylation is an important protein modification in which Ser/Thr residues are modified with a single β-N-acetylglucosamine [1] . O-GlcNAcylation is generally considered to be a post-translational modification, but it may also occur co-translationally [2] . In living organisms, O-linked β-N-acetylglucosamine (O-GlcNAc) is dynamically regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). O-GlcNAc has been found to modify many proteins, and may play important roles in regulating diverse cellular processes such as metabolism [3] , signalling [4] , transcription [5] , and protein quality control [2] .
Recently, the possible link between O-GlcNAc and Alzheimer's disease (AD) has attracted attention [6, 7] . Most cases of AD (∼99%) are sporadic and may be caused by multiple aetiological factors, including epigenetic, environmental and metabolic factors. Metabolic factors may play the most significant roles in the development of this disease [8] . One of the earliest and most obvious brain metabolic changes is decreased brain glucose uptake and metabolism [9] . As a known molecular sensor of intracellular metabolism and stress, O-GlcNAcylation may mediate several pathways in disrupted brain metabolism. Thus, a comprehensive understanding of brain protein O-GlcNAcylation and its dysregulation in AD may contribute to a better understanding of the molecular mechanisms leading to its sporadic development.
However, issues such as the low levels and labile nature of O-GlcNAcylation have posed significant analytical challenges for the direct proteomic characterizaBrain protein O-GlcNAcylation in Alzheimer's disease 79 proteomics field are increasingly enabling high-fidelity mass spectrometry (MS) characterization of O-GlcNAc peptides [10] with techniques such as lectin affinity chromatography [11] and chemoenzymatic photocleavage (CEPC) [12] methods for enrichment, electron transfer dissociation (ETD) for site determination [13] , and stable isotope labelling methods for precise quantification [14] [15] [16] . In this study, we developed an integrated proteomic pipeline consisting of isobaric tandem mass tag (TMT) labelling [17] , high-pH reversed-phase liquid chromatography (bRPLC) fractionation and concatenation [18] , CEPC enrichment [12, 19] and LC-MS/MS for comprehensive, quantitative and large-scale analysis of protein O-GlcNAc. Application of this proteomic pipeline to characterize O-GlcNAcylation in postmortem human brains from individuals with or without AD led to the identification of a total of 1850 O-GlcNAc peptides from 530 proteins (with 1094 confidently assigned O-GlcNAc sites), among which 131 O-GlcNAc peptides were altered significantly in AD.
Materials and methods

Brain tissue homogenization and digestion
Autopsied postmortem frozen brain tissue samples from 10 pathologically confirmed AD cases and 10 matched controls with no neurological pathologies or symptoms (supplementary material, Table S1 ) were obtained from the Banner Sun Health Research Institute Brain and Body Donation Program (Sun City, AZ, USA). The use of the frozen human brain tissue was in accordance with the National Institutes of Health guidelines, and was approved by the Institutional Review Boards of New York State Institute for Basic Research and the Pacific Northwest National Laboratory. All AD cases were in Braak stage V or VI. AD cases and controls were matched in terms of age at the time of death, postmortem interval, and gender. The grey matter (∼0.1 g) of the mid-frontal gyrus of each sample was homogenized in 600 μl of lysis buffer [8 M urea, 60 mM NH 4 HCO 3 , 1 × HALT phosphatase inhibitor cocktail (Pierce, Waltham, MA, USA), 20 μM PUGNAc, and 10 mM dithiothreitol]. After homogenization, proteins were reduced at 37 ∘ C for 1 h, and alkylated at room temperature for 30 min in the dark (25 mM iodoacetamide). The sample was then diluted one-fold with 50 mM NH 4 HCO 3 and 2 mM CaCl 2 , and digested twice with trypsin (1:50 enzyme/substrate ratio), first for 3 h at 37 ∘ C, and then overnight at room temperature. The sample was acidified with 10% trifluoroacetic acid, and centrifuged at 14 000 × g for 20 min before being desalted by C18 solid phase extraction and dried. Peptide concentrations were determined with the bicinchoninic acid assay (Pierce).
TMT labelling and fractionation
A pooled reference was first created with an equal contribution from each sample. Each individual sample containing ∼600 μg of peptides was dried and dissolved in 180 μl of 250 mM sodium borate (pH 8.6), before 5 mg of TMT reagent in 430 μl of acetonitrile was added. The TMT-6 labelling scheme is shown in supplementary material , Table S2 . The reaction was allowed to proceed at room temperature for 90 min before being terminated with 5% hydroxylamine. Samples with different TMT labelling in the same TMT-6 experiment were combined, acidified and desalted on a C18 solid phase extraction column, and this was followed by bRPLC fractionation and concatenation [18] . The mobile phases were: (A) 10 mM triethylammonium bicarbonate (TEAB) (pH 7.5); and (B) 10 mM TEAB and 90% acetonitrile (pH 7.5). Sample separation was carried out at a flow rate of 0. 
Enrichment of O-GlcNAc peptide
Enrichment of O-GlcNAc peptide from the fractions was performed with the CEPC method [12, 19] , with minor modifications. After removal of a small aliquot (∼10 μg) for direct LC-MS/MS analysis to provide global protein quantification and as a means for loading normalization, the fractionated peptides (∼300 μg) were dried in vacuum and resuspended in 1.1 ml of 20 mM HEPES (pH 7.9), and 80 μl of 100 mM MnCl 2 , 75 μl of 0.5 mM UDP-GalNAz, 62 μl of GalT1 and 2.5 μl of PNGase F (New England Biolabs, Ipswich, MA, USA) were added (N-glycans were removed by PNGase F to improve the specificity of the O-GlcNAc enrichment). The mixtures were incubated at 4 ∘ C for ∼20 h, and then at room temperature for 3 h. After this glycotransfer step, the peptides were reacted with 1 mM biotin-PEG-PC-alkyne (Ambergen, Watertown, MA, USA) in 20 mM HEPES (pH 7.9), with 0.8 mM CuSO 4 , 4 mM tris(3-hydroxypropyltriazolylmethyl)amine, 20 mM sodium ascorbate and 20 mM aminoguanidine as the catalyst for copper-catalysed alkyne-azide cycloaddition [20] . Extra reagents were removed by C18 and strong cation exchange solid phase extractions. The peptides were neutralized with phosphate-buffered saline (PBS), incubated with NeutrAvidin agarose resin (Pierce) for 2 h at room temperature, and washed thoroughly with 2 M urea in PBS (six times), 4 M urea in 50 mM NH 4 HCO 3 (six times), 2 M NaCl (six times), water (once), and 70% methanol (five times). The O-GlcNAc peptides were released from the resin by application of 365-nm ultraviolet (UV) radiation for 25 min. One-quarter of the enriched sample was injected for LC-MS/MS analysis. Table S2 ), both at a flow rate of 300 nl/min. Full MS spectra (400-2000 m/z) were acquired with a resolution of 60 000. The top 10 most intensive precursor ions were selected for MS/MS with alternating ETD and higher-energy collision dissociation (HCD), both with an isolation window of 2 Da. An activation time of 100 ms and supplemental activation were used in ETD, and the product ions were detected in an ion trap. A normalized collision energy of 32% was used in HCD fragmentation, and the product ions were detected in the Orbitrap with a resolution of 7500.
MS/MS identification
As previously reported [19] , the MS raw data were searched against a UniProt protein database (version 2015_04) with MS-GF+ (v9881) [21] . The searching parameters were: precursor ion mass tolerance (±10 p.p.m.), partial tryptic specificity, dynamic oxidation of Met (15.9949 Da), static TMT-6 labelling on the N-terminus and on Lys (229.1629 Da), and dynamic O-GlcNAcylation on Ser and Thr (502.2023 Da). The search results from HCD and ETD spectra were first filtered separately to obtain a false identification rate of <1% at the peptide level. The identification of an O-GlcNAc peptide was then confirmed/filtered by the presence of the diagnostic 300.13 m/z ion in subsequent corresponding HCD spectra [19] . An Ascore of >13 was required for confident O-GlcNAc site assignment (P < 0.05) [22] .
Quantitative and statistical analysis
The intensities of all six TMT reporter ions were extracted by the use of MASIC software [23] . The reporter ion intensities from different scans and/or different fractions corresponding to the same O-GlcNAc peptide or protein (in the case of global proteome analysis) were summed. Relative peptide/protein abundance was then calculated as the ratio of sample abundance to abundance of the pooled reference (in the 126 channel) by use of the summed reporter ion intensities (i.e. sample/reference), and log 2 -transformed to obtain final relative expression values. This allows comparison of relative protein abundances across the entire sample set with minimum variation from each TMT-6 experiment. The strategy of using a common 'internal' reference for merging of different multiplexed experiments in isobaric labelling analysis has been demonstrated recently to be a highly effective and reliable method for large-scale quantitative proteomics analysis [24, 25] .
To correct for potential differences in sample loading in the same TMT-6 experiment, the median log 2 relative abundances of the peptides present in each of the original labelled but not enriched samples were computed and re-centered, and the normalization factors obtained therein were applied to corresponding O-GlcNAc data. A moderated t-test was performed with the limma package [26] . The null hypothesis was that there is no difference between the AD and control groups. To correct for multiplicity of hypothesis testing, individual O-GlcNAc or protein values were adjusted by converting them to q-values with the corresponding R package [27] .
Gene function classification and pathway analysis of the O-GlcNAc proteins in AD were performed with DAVID (https://david.ncifcrf.gov/) [28] . Motif analysis was performed with pLogo (https://plogo.uconn.edu/) [29] .
Western blotting
Tissue lysates containing 200 μg of protein were subjected to reduction (10 mM dithiothreitol) and alkylation (90 mM iodoacetamide) before being precipitated with the methanol/chloroform method and reconstituted in 40 μl of 1% sodium dodecyl sulphate (SDS) and 20 mM HEPES (pH 7.9). The sample was then subjected to GalNAz labelling with the Click-iT labelling kit (ThermoFisher C33368, Waltham, MA, USA), according to the manufacturer's instructions. The azide-labelled proteins were linked with a 5-kDa PEG molecule via copper-free click chemistry, as reported previously [30] . After the reactions, the proteins were precipitated and reconstituted for SDS polyacrylamide gel electrophoresis, transferred to a poly(vinylidene difluoride) membrane, and detected with rabbit antibodies against protein quaking (QK1) or synaptopodin (SYNPO) (Pierce PA5-30563 and PA5-21062; 1:1 000) by use of the Fast Western Kits (Pierce) with β-tubulin antibody as a loading control.
Data deposition
The LC-MS/MS raw data, database searching results and TMT reporter ion intensity information have been deposited in the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org dataset PXD004510).
Results
Integrated quantitative proteomics for O-GlcNAc modification
An overview of our new quantitative proteomic pipeline for comprehensive O-GlcNAc analysis is shown in Figure 1A . It has several attractive features: (1) TMT labelling allows for precise quantification and sample multiplexing, and hence much increased analysis throughput, and can be applied to tissues, cells, or biofluids; (2) the 'common' reference strategy [24, 25] allows for robust O-GlcNAc quantification in a large sample cohort; (3) the CEPC method ( Figure 1B) for enriching O-GlcNAc peptides is robust and highly specific and sensitive; and (4) every precursor is analysed by both ETD and HCD for peptide identification and quantification and O-GlcNAc site determination. A pair of alternating ETD/HCD spectra are shown in Figure 1C , D.
Mapping of O-GlcNAc in human brain
A total of 1850 unique peptides (supplementary material, Table S3 ) from 530 O-GlcNAc proteins (supplementary material, Table S4 ) were identified. Gene ontology (GO) classification results for these O-GlcNAc proteins are shown in supplementary material, Figure S1 . These results supported the involvement of O-GlcNAc in various cellular functions in the brain, including cytoskeleton organization, axonogenesis, cell 82 S Wang et al adhesion, and regeneration. KEGG pathway analysis indicated the involvement of O-GlcNAc in extracellular matrix (ECM)-receptor interactions, focal adhesion, lysosomes, adherens junctions, long-term potentiation, and the mitogen-activated protein kinase signalling pathway. Interestingly, nine secreted proteins related to the ECM (TNXB, TNC, COL6A2, COL6A3, LAMA5, LAMC1, LAMB2, HSP2, and LAMA), and some membrane proteins, including NOTCH, were also found to be O-GlcNAcylated. O-GlcNAcylation on these proteins may be the result of the action of the epidermal growth factor domain-specific O-GlcNAc transferase, which is located in the endoplasmic reticulum and is responsible for O-GlcNAcylation of extracellular proteins [31] .
A total of 1094 O-GlcNAcylation sites (supplementary material, Table S5 ) were unambiguously determined (≥95% confidence). More than 85% of the O-GlcNAc sites were identified from ETD (data not shown), and HCD provided additional O-GlcNAc peptide identifications as well as important information on the oxonium ion (additional evidence of O-GlcNAcylation) and TMT reporter ion intensities (quantification). Eighty-six sites were in the O-GlcNAc database from the Phosphosite website (http://www .phosphosite.org) [32] , which covered 411 previously reported O-GlcNAcylation sites from human proteins. Many of the O-GlcNAc sites have reciprocal (20.3%) or proximal (within ±10 amino acids, 54.3%) relationships with phosphorylation sites (supplementary material, Table S5 ). Moreover, most (98.9%) of the O-GlcNAc-modified proteins identified in the present study are known phosphoproteins (supplementary material, Table S4 ). In our previous study, significantly fewer O-GlcNAc sites found in the healthy mouse brain appeared to have reciprocal (4.6%) or proximal (within ±10 amino acids, 21.4%) relationships with phosphorylation sites [19] .
Interestingly, there were almost no differences in the motifs of O-GlcNAc modification between human ( Figure 2 ) and mouse ( Figure S2) . Moreover, the motifs of Ser O-GlcNAcylation and Thr O-GlcNAcylation were surprisingly similar (Figure 2 ; supplementary material, Figure S2 ). This brain O-GlcNAcylation motif feature is consistent with that predicted by the O-GlcNAc prediction programs YinOYang 1.2 server and OGlcNAcScan [33] , and predictions based on 410 experimentally verified O-GlcNAcylation sites extracted from dbOGAP, OGlycBase, and UniProtKB [34] . Thus, the O-GlcNAcylation motifs appear to be fairly well conserved across various species and in various organs. abundance in AD (q < 0.05; supplementary material, Table S6 ; Figure 3A ). The changes in these O-GlcNAc peptides across the individual samples are shown as a heatmap in Figure 3B . GO analysis of the proteins carrying these peptides showed that these proteins are involved in zinc ion binding, mRNA transport, transcription, chromatin modification, and cell projection organization, as well as the focal adhesion, ECM-receptor interaction and prion disease pathways ( Figure 3C ). Interestingly, among these 131 O-GlcNAc peptides, only 12 peptides from three proteins [SYNPO, ankyrin-3 (ANK3), and SH3RF1) showed decreased abundance in AD, whereas the majority, i.e. 119 peptides, showed increased abundance.
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We briefly analysed an aliquot of the TMT-6-labelled, unenriched peptide samples for correction of loading differences in the TMT channels for the enriched O-GlcNAc samples. This also allowed us to initially examine whether the changes in O-GlcNAc abundance were affected by the changes in protein expression. We quantified a total of 1635 proteins, and the results are shown in supplementary material, Table S7 . Among these quantified proteins, only 27 (1.65%) showed significant changes (q < 0.05) in AD (supplementary material, Figures S3 and S4) , which is a much lower frequency of changes than that observed in the O-GlcNAcylated peptides (>20% differed significantly). Moreover, statistical tests of the global peptide quantification results with (supplementary material, Table S7 ) and without (supplementary material, Table S9 ) protein roll-up showed that the proportion of differentially abundant global peptides appeared to be even lower (0.35%) than that for proteins (supplementary material, Table S10), confirming the significantly higher level of change in O-GlcNAcylation in these AD samples.
The expression of O-GlcNAc cycling enzymes (OGT and OGA, both of which were quantified in our study) may be an important contributor to the differences in O-GlcNAc abundance. However, we did not find significant changes in the abundances of these enzymes in AD brains (supplementary material, Figure S5 ; q = 0.60 and q = 0.224 for OGT and for OGA, respectively). These global proteome results suggest that most of the changes in O-GlcNAc abundance were due to changes at the O-GlcNAc modification level rather than protein abundance.
The net changes in O-GlcNAcylation (i.e. the change in O-GlcNAcylation on top of the change in protein expression) were calculated for 306 O-GlcNAc peptides for which the protein expression data were also available (supplementary material, Table S8 ). For these O-GlcNAc net changes, a heatmap is shown in supplementary material, Figure S6 , and a volcano plot is shown in supplementary material, Figure S7 . Twelve peptides showed increases in O-GlcNAc net changes and 12 peptides showed decreases in O-GlcNAc net changes (q < 0.05; Table 1 ).
Initial validation of protein O-GlcNAcylation level
Western blotting was performed to initially verify the MS quantification data for two proteins, i.e. SYNPO and QKI. The O-GlcNAc was first labelled with GalNAz by use of the Click-iT kit, and a PEG tag (5 kDa) [35] was then linked to the azide through copper-free click chemistry [30] . Anti-SYNPO and anti-QKI antibodies were used to visualize the proteins in the non-glycosylated and glycosylated forms (Figure 4) . O-GlcNAcylation of SYNPO decreased in the AD samples whereas that of QKI increased in these samples as compared with control samples. These data are in agreement with the MS quantification results.
Discussion
AD has two types, early-onset familial AD and late-onset sporadic AD. Most (∼99%) cases are sporadic and appear to be caused by multiple aetiological factors through several pathogenetic mechanisms [36] . Our findings of the alterations of multiple O-GlcNAcylated proteins in sporadic AD brains are consistent with the complex nature of the disease. These altered O-GlcNAcylated proteins cover various functional categories, with more proteins being involved in mRNA transport and transcriptional and post-transcriptional regulation of gene expression. A pivotal role of epigenetic dysregulation in the development of sporadic AD has gained much attention recently, and could result from or through the altered O-GlcNAcylation of these proteins [37, 38] .
There have been several studies on the overall O-GlcNAcylation level in AD using antibody-based approaches, but with conflicting results (downregulated [39, 40] and upregulated [41, 42] ). Note that no PUGNAc was used to preserve O-GlcNAc in these studies. With PUGNAc used in the present study, our MS quantification data showed that more O-GlcNAc peptides increased in abundance rather than decreased in abundance in AD brains. The MS-based methods also provided a powerful tool for site-specific quantification of O-GlcNAcylation (both total and 'net' changes in abundance) of hundreds of brain proteins simultaneously (623 O-GlcNAc peptides covering 284 proteins in this study).
To determine whether the changes in O-GlcNAc peptide abundance result from the alteration of native protein expression or the alteration of OGT/OGA function/activity, two approaches were taken. First, the same TMT-6-labelled samples without enrichment for O-GlcNAc peptides were analysed, and the results were compared with the O-GlcNAc results. The remarkable differences noted between the O-GlcNAc and global proteome analyses (>20% versus <2% changed) suggest selective alterations of either protein O-GlcNAcylation levels or the expression levels of O-GlcNAcylated proteins. Second, we analysed the net change in O-GlcNAcylation of 306 O-GlcNAc peptides for which protein expression data were also available. We found significant increases and decreases in net changes of O-GlcNAc of 12 and 12 peptides, respectively. Therefore, the O-GlcNAc cycling enzymes have functioned differently on these sites/peptides than on other sites in the AD brain. The imbalance of O-GlcNAc cycling on these sites may be due to the changes in the structure of the proteins that carry these O-GlcNAc sites, or differential neuronal cell loss and/or glial response in AD.
Among the proteins carrying altered OGlcNAcylation in AD, ANK3 (also called ankyrin-G), SYNPO and A-kinase anchor protein 11 (AKAP11) are of particular interest. ANK3 is an adaptor protein expressed in neurons and epithelial cells, and mediates the attachment of integral membrane proteins to the 86 S Wang et al spectrin-actin-based membrane cytoskeleton. This linkage is required to maintain the integrity of the plasma membrane and to anchor specific transmembrane proteins in the plasma membrane. The pivotal role of the disrupted integrity of the brain plasma membrane in the AD brain has been recognized [43] . Altered trafficking of amyloid β (Aβ) peptide and other critical proteins in the membrane is thought to be crucial to the development of AD [44] . A previous gene linkage study found a significant association between sporadic AD and the single-nucleotide polymorphism of ANK3 [45] . Mislocalization of ANK3 and its role in the disruption of axon polarity have been recently reported [46] . Our findings of the marked decrease in ANK3 O-GlcNAcylation in AD brains may open a new avenue for further investigation of its role in the molecular pathogenesis of AD, such as the influence of O-GlcNAc of ANK3 in membrane integrity and axon polarity. SYNPO is a postsynaptic protein that is important for synaptic plasticity [47] . Our finding of the marked decrease in SYNPO O-GlcNAcylation in AD brains suggests that it has a role in the synaptic dysfunction and degeneration that occur in AD. AKAP11 has one O-GlcNAc site (Ser719) that showed a significant increase in abundance in AD. Change in O-GlcNAc on this site is worthy of attention, because AKAP11 is related to important kinases in AD. AKAP11 was reported to target protein kinase-A, which may inhibit glycogen synthase kinase 3α, a kinase regulating the production of Aβ [48] . AKAP11 also binds to glycogen synthase kinase 3β [49] , which is responsible for the phosphorylation of tau protein [50] . Thus, the function of this site is of great interest for further research, and highlights the importance of the crosstalk between O-GlcNAc and phosphorylation in the pathology of AD.
It has been reported that O-GlcNAc modifies several important brain proteins, such as tau [39, 40, 51, 52] and Aβ [53] [54] [55] , which have been implicated in the pathogenesis of AD. We also detected O-GlcNAc-modified tau peptides (supplementary material, Table S3 ), but too many missing values occurred (i.e. detected in only <50% of the samples) in the present study. Thus, tau O-GlcNAcylation could not be quantified reliably. O-GlcNAcylated peptides from Aβ were not detectable in the present study, probably because of the very low level of O-GlcNAcylation of Aβ as compared with other proteins, e.g. bassoon. Nevertheless, the regulation of O-GlcNAcylation on these proteins may still be important for the pathogenesis of AD, as reported by previous studies.
In conclusion, the present study is the most comprehensive quantitative proteomic study for brain O-GlcNAcylation to date, reporting O-GlcNAc modifications on >1000 sites from human brain tissue samples. The use of multiplexed isobaric labelling with the pooled common reference strategy enabled us to compare the levels of hundreds of O-GlcNAc peptides in 20 individual samples quickly and reliably, and to discover changes in >100 O-GlcNAc peptides in AD. The number of samples analysed in this study is still relatively small, so some of the findings could be underpowered; it is also possible that not all of these changes were due to AD. However, the initial identification of altered O-GlcNAc peptides/proteins, such as AKAP11, opens new avenues for future investigations of the molecular mechanisms of AD. Moreover, the quantitative proteomics analytical pipeline developed and implemented in the current study can be further expanded to accommodate the need for higher throughput (e.g. by using TMT-10) as well as integrated proteome, phosphoproteome and/or O-GlcNAc proteome analysis (e.g. via sample splitting or sequential enrichment). The increased number of samples to be included in the comparison and the integrated proteome/phosphoproteome/O-GlcNAc-ome analysis will help to prioritize some of these findings for further verification, and shed light on the crosstalk between protein phosphorylation and O-GlcNAcylation in AD pathology. Table S1 . Human brain tissues used in this study Table S2 . TMT-6 labeling of the human brain samples 
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